# US 2010/0168101 A1 · Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168101 A1
- Document ID: US20100168101A1
- Status: Published application
- Kind: A1
- Application number: 12/645,952
- Filed: 2009-12-23
- Published: 2010-07-01
- Earliest claimed: 2001-10-30
- Assignees: Applied Research Systems ARS Holding N.V.
- Inventors: Agnes BOMBRUN; Patrick Gerber; Dennis Church
- Web page: https://patentgrep.com/patent/US20100168101A1

## CPC

- C07D 257/04: Five-membered rings
- A61K 31/404: Indoles, e.g. pindolol
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 209/38: in positions 2 and 3, e.g. isatin
- C07D 209/40: Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
- C07D 211/62: attached in position 4
- C07D 295/096: with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 307/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 317/60: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of oxindole hydrazide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs, in particular of PTP1B, TC-PTP, SHP and GLEPP-1. The present invention is furthermore related to novel oxindole hydrazide derivatives and method of preparation thereof.

## Claims

### Claim 1

A method for treating and/or preventing at least one metabolic disorder mediated by insulin resistance or hyperglycemia, which comprises:
administering to a mammal in need thereof a pharmaceutically acceptable composition comprising an oxindole hydrazide according to formula (I)
as well as its tautomers, geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein
R1 is halogen or —(C═O)N—(C6-C18)-alkyl, d is 1 to 4;
R2 is H, —CO—NH—R or —(CH2)u—CO—OR, wherein u is an integer from 1 to 7 and R is H or (C1-C6)-alkyl;
R3 is H or C1-C6-alkyl;
R4, R5, R6 and R7 are each independently from each other selected from the group consisting of H, halogen, —NO2, —OH, (C1-C6)-alkyl, 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl which may contain 1-2 further heteroatoms selected from O, N or S, (C1-C6)-alkyl-heterocycloalkyl wherein said heterocyclolalkyl may contain 1-2 further heteroatoms selected from O, N or S, aryl, (C1-C6)-alkyl-aryl, heteroaryl, (C1-C6)-alkyl-heteroaryl;
R8 is selected from the group comprising or consisting of H, halogen, hydroxy, acyl, amino, carboxy, cyano, nitro, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkyl carboxy, C1-C6-alkyl acyl, C1-C6-alkyl alkoxycarbonyl, carbonylamino, hydrazinocarbonyl, aminocarbonyl, C1-C6-alkyl aminocarbonyl, C1-C6-alkyl acyloxy, acylamino, C1-C6-alkyl acylamino, ureido, C1-C6-alkyl ureido, C1-C6-alkyl carbamate, C1-C6-alkyl amino, C1-C6 alkoxy, C1-C6-alkyl alkoxy, sulfanyl, C1-C6-alkyl sulfanyl, sulfinyl, C1-C6-alkyl sulfinyl, sulfonyl, sulfonylamino, C1-C6-alkyl sulfonyl, C1-C6-alkyl sulfonylaminoaryl, aryl, heteroaryl, C3-C8-cycloalkyl or heterocycloalkyl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl, C2-C6-alkenyl-aryl or -heteroaryl, C2-C6-alkynyl aryl or -heteroaryl
A is selected from the group consisting of a bond, —O—, —S—, —SO—, —SO2—, amino, urea, sulfonylamino or acylamino;
B is arylene, heteroarylene, heterocycloalkylene or cycloalkylene;
X is C, S or SO;
m, n and p are each independently from each other an integer from 0 to 6; m is also 0, 1 or 2, while n is 0 or 1, and p is 1 or 2;
wherein said metabolic disorders mediated by insulin resistance or hyperglycemia is at least one disorder selected from the group consisting of diabetes type I diabetes type II, diabetes type I and III, inadequate glucose tolerance, insulin resistance, hyperlipi-demia, hypertriglyceridemia, hypercholesterolemia, obesity, and polycystic ovary syndrome (PCOS).

### Claim 2 (depends on 1)

A method according to claim 1, wherein R8 of the oxindole hydrazide is selected from the group consisting of H, halogen, cyano, (C1-C6)alkyl, aryl, heteroaryl, —SO—R9, —SO2—R9, (C1-C6)alkyl-SO2—R9, —NO2, —N(R9)2, (C1-C6)-alkyl-O—R9, —SR9, —SO2—R9, —(C═O)O—R9, —(C═O)—R9, —(C═O)N(R9)2, —(C═O)NH—R9, —(C═O)NR9—N(R9)2, —NR9—(C═O)—N(R9)2, —NR9—(SO2—R9) —NH—(C═O)—R9, (C1-C6)-alkyl-NH—(C═O)—R9, —NR9—(C═O)—R9 wherein R9 is selected from the group consisting of H, C3-C8 cycloalkyl, 3-8 membered heterocycloalkyl which may contain 1-2 further heteroatoms selected from O, N or S, (C1-C6)-alkyl-heterocycloalkyl wherein said heterocycloalkyl may contain 1-2 further heteroatoms selected from O, N or S, aryl, (C1-C6)-alkyl-aryl, (C1-C6)-alkoxy-aryl, heteroaryl, (C1-C6)-alkyl-heteroaryl or (C1-C6)-alkoxy-heteroaryl, (C1-C6)-alkyl, (C1-C6)-alkyl-COOR10 wherein R10 is H or (C1-C6)alkyl or —NH2,

### Claim 3 (depends on 1)

A method according to claim 1, wherein said metabolic disorder is diabetes type II.

### Claim 4 (depends on 1)

A method according to claim 1, wherein B in the oxindole hydrazide is independently selected from the group consisting of phenyl, naphthyl, phenantrenyl, pyrrolyl, furyl, thienyl, imidazolyl, pyridyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, [1,3]thiazolo[3,2-b][1,2,4]triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, benzo(2,1,3)oxadiazolyl, benzo(1,2,3)oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, tetrazolyl, 1,3,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, pyridazinyl, pyrimidyl, quinolizinyl, quinazolinyl, pthalazinyl, quinoxalinyl, cinnolinyl, napthyridinyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, xanthenyl, benzoquinolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, oxolanyl, pyrolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, imidazolidinyl, 1,2,4-oxadiazolidinyl, 1,2,5-oxadiazolidinyl, 1,3,4-oxadiazolidinyl, isoxazolidinyl or morpholinyl.

### Claim 5 (depends on 4)

A method according to claim 4, wherein B of the oxindole hydrazide is selected from the group consisting of phenyl, biphenyl, benzo(1,2,5)-oxadiazolyl, furyl, thiadiazolyl, thienyl, thiazolyl, indolyl, piperidinyl, pyridyl, 1,2,3-triazolyl, 1,2,4-triazolyl and tetrazolyl.

### Claim 6 (depends on 1)

A method according to claim 1, wherein R4, R5, R6 and R7 of the oxindole hydrazide are each independently from each other selected from the group consisting of H and (C1-C6)-alkyl.

### Claim 7 (depends on 1)

A method according to claim 1, wherein in the oxindole hydrazide R1 is Br or I and d is 1.

### Claim 8 (depends on 7)

A method according to claim 7, wherein in the oxindole hydrazide n and m are each 0, A is a bond or O, B is phenyl, p is 1 and R8 is —NH—CO—(C1-C6-alkyl)-Ar1, or —O—Ar1 wherein Ar1 is a phenyl group.

### Claim 9 (depends on 1)

A method according to claim 1, wherein the oxindole hydrazide is represented by formula (Ia)
wherein m′ is 0 or 1 R8 is selected from the group consisting of H, halogen, cyano, (C1-C6)alkyl, aryl, heteroaryl, —SR9, —SO—R9, —SO2—R9, (C1-C6)alkyl-SO2—R9, —NO2, —N(R9)2, —OR9, (C1-C6)-alkyl-O—R9, —(C═O)O—R9, —(C═O)—R9, —(C═O)N(R9)2, —(C═O)NH—R9, —(C═O)NR9—N(R9)2, —NR9—(C═O)—N(R9)2, —NR9—(SO2—R9), —NH—(C═O)—R9, (C1-C6)-alkyl-NH—(C═O)—R9, —NR9—(C═O)—R9 wherein R9 is selected from the group consisting of H, C3-C8 cycloalkyl, 3-8 membered heterocycloalkyl which may contain 1-2 further heteroatoms selected from O, N or S, (C1-C6)-alkyl-heterocycloalkyl wherein said heterocycloalkyl may contain 1-2 further heteroatoms selected from O, N or S, aryl, (C1-C6)-alkyl-aryl, (C1-C1)-alkoxy-aryl, heteroaryl, (C1-C6)-alkyl-heteroaryl or (C1-C6)-alkoxy-heteroaryl, (C1-C6) alkyl, C1-C6)-alkyl-COOR10 wherein R10 is H or (C1-C6)alkyl or —NH2.

### Claim 10 (depends on 9)

A method according to claim 9, wherein in the oxindole hydrazide R8 is —NO2, —NH—(C═O)—R9 or —COOR9.

### Claim at position 11

11-19. (canceled)

### Claim 20

A medicant which comprises, a pharmaceutically acceptable medium and an oxindole hydrazide of formula (II)
wherein:
A is O or a bond;
B is independently selected from the group consisting of arylene, heteroarylene, heterocycloalkylene or cycloalkylene;
R8 is selected in the group consisting of H, halogen, cyano, (C1-C6)alkyl, aryl, heteroaryl, —SO—R9, —SO2—R9, (C1-C6)alkyl-SO2—R9, —NO2, —N(R9)2, (C1-C6)-alkyl-O—R9, —SR9, —SO2—R9, —(C═O)O—R9, —(C═O)—R9, —(C═O)N(R9)2, —(C═O)NH—R9, —(C═O)NR9—N(R9)2, —NR9—(C═O)—N(R9)2, —NR9—(SO2—R9), —NH—(C═O)—R9, (C1-C6)-alkyl-NH—(C═O)—R9, —NR9—(C═O)—R9 wherein R9 is selected from the group consisting of H, C3-C8 cycloalkyl, 3-8 membered heterocycloalkyl which may contain 1-2 further heteroatoms selected from O, N or S, (C1-C6)-alkyl-heterocycloalkyl wherein said heterocycloalkyl may contain 1-2 further heteroatoms selected from O, N or S, aryl, (C1-C6)-alkyl-aryl, (C1-C6)-alkoxy-aryl, heteroaryl, (C1-C6)-alkyl-heteroaryl or (C1-C6)-alkoxy-heteroaryl, C1-C6)-alkyl, (C1-C6)-alkyl-COOR10 wherein R10 is H or (C1-C6)alkyl or —NH2;
m′ is 0 or 1;
p is an integer from 1 to 3;
for use as a medicament.

### Claim 21

A method for treating and/or preventing at least one metabolic disorder mediated by insulin resistance or hyperglycemia, which comprises:
administering to a mammal in need thereof a pharmaceutically acceptable composition comprising an oxindole hydrazide of formula (II)
wherein:
A is O or a bond;
B is independently selected from the group consisting of arylene, heteroarylene, heterocycloalkylene or cycloalkylene;
R8 is selected in the group consisting of H, halogen, cyano, (C1-C6)alkyl, aryl, heteroaryl, —SO—R9, —SO2—R9, (C1-C6)alkyl-SO2—R9, —NO2, —N(R9)2, (C1-C6)-alkyl-O—R9, —SR9, —SO2—R9, —(C═O)O—R9, —(C═O)—R9, —(C═O)N(R9)2, —(C═O)NH—R9, —(C═O)NR9—N(R9)2, —NR9—(C═O)—N(R9)2, —NR9—(SO2—R9), —NH—(C═O)—R9, (C1-C6)-alkyl-NH—(C═O)—R9, —NR9—(C═O)—R9 wherein R9 is selected from the group consisting of H, C3-C8 cycloalkyl, 3-8 membered heterocycloalkyl which may contain 1-2 further heteroatoms selected from O, N or S, (C1-C6)alkyl-heterocycloalkyl wherein said heterocycloalkyl may contain 1-2 further heteroatoms selected from O, N or S, aryl, (C1-C6)-alkyl-aryl, (C1-C6)-alkoxy-aryl, heteroaryl, (C1-C6)-alkyl-heteroaryl or (C1-C6)-alkoxy-heteroaryl, (C1-C6)-alkyl, (C1-C6)-alkyl-COOR10 wherein R10 is H or (C1-C6)alkyl or —NH2;
m′ is 0 or 1;
p is an integer from 1 to 3,
wherein at least one metabolic disorders mediated by insulin resistance or hyperglycemia is selected from the group consisting of diabetes type I, diabetes type II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, and polycystic ovary syndrome (PCOS).

### Claim at position 14

22-24. (canceled)

### Claim 25

A compound of formula (B) selected from the group consisting of:
N-[4-(Hydrazinocarbonyl)phenyl]-3-phenylpropanamide;
Phenylmethyl-4-[(N-aminocarbamoyl)methoxy]benzoate;
N-[4-(Hydrazinocarbonyl)phenyl]-2-furamide;
N-[4-(Hydrazinocarbonyl)phenyl]hexanamide;
4-Cyano-N-[4-(hydrazinocarbonyl)phenyl]benzamide;
4-(Hexyloxy)-N-[4-(hydrazinocarbonyl)phenyl]benzamide;
4-Heptyl-N-[4-(hydrazinocarbonyl)phenyl]benzamide;
4-(2-Hydrazino-2-oxoethoxy)benzoic acid;
4-Cyano-N-[3-(hydrazinocarbonyl)phenyl]benzamide;
4-(Hydrazinocarbonyl-N-(3-[(trifluoromethyl)sulfonyl]phenyl)benzamide;
4-Chloro-N-[4-(hydrazinocarbonyl)benzyl]benzamide;
1-Benzoyl-4-piperidinecarbohydrazide;
N-[4-(Hydrazinocarbonyl)phenyl]-2-phenoxyacetamide;
N-[4-(Hydrazinocarbonyl)benzyl]-3-nitrobenzamide;
N-[4-(Hydrazinocarbonyl)phenyl][1,1′-biphenyl]-4-carboxamide;
3-(1,3-Benzodioxol-5-yl)-N-[4-(hydrazinocarbonyl)phenyl]propanamide;
4-{[4-(Hydrazinocarbonyl)benzoyl]amino}benzoic acid;
3-(3,4-Dihydroxyphenyl)-N-[4-(hydrazinocarbonyl)phenyl]propanamide;
N-[4-(Hydrazinocarbonyl)phenyl]-3-phenylpropanamide;
N-[4-(Hydrazinocarbonyl)phenyl]-2-phenoxyacetamide;
N-[4-(Hydrazinocarbonyl)benzyl]-3-nitrobenzamide;
Methyl-3-(2-hydrazino-2-oxoethoxy)benzoate;
2-[4-(1H-Tetrazol-5-yl)phenoxy]acetohydrazide;
4-(Hydrazinocarbonyl)-N-phenylbenzamide;
4-[4-(Morpholinylmethyl)phenoxy]benzohydrazide;
4-(2-Hydrazinocarbonyl-ethyl)-benzoic acid methyl ester;
2-[4-(1H-Tetrazol-5-yl)phenoxy]acetohydrazide;
2-(4-Cyanophenoxy)acetohydrazide;
Methyl-4-[methyl(3-phenylpropanoyl)amino]benzoate;
N-[4-(hydrazinocarbonyl)phenyl]-N-methyl-3-phenylpropanamide;
Methyl-(5-iodo-2,3-dioxo-2,3-dihydro-1H-indol-1-yl)acetate;
Methyl-4-{[3-(1,3-benzodioxol-5-yl)propanoyl]amino}benzoate;
tert-Butyl 2-{4-[(4-methoxy-4-oxobutanoyl)amino]benzoyl}hydrazinecarboxylate;
tert-Butyl 2-{4-[(6-methoxy-6-oxohexanoyl)amino]benzoyl}hydrazinecarboxylate;
tert-Butyl 2-(4-{[4-(methoxycarbonyl)benzoyl]amino}benzoyl)hydrazinecarboxylate;
tert-Butyl 2-{4-[(9-methoxy-9-oxononanoyl)amino]benzoyl}hydrazinecarboxylate;
tert-Butyl 2-{4-[(6-methoxy-6-oxohexanoyl)amino]benzoyl}hydrazinecarboxylate;
4-({[4-(Methoxycarbonyl)benzoyl]amino}methyl)benzoic acid;
tert-Butyl 2-[4-({[4-(methoxycarbonyl)benzoyl]amino}methyl)benzoyl]hydrazine-carboxylate;
tert-Butyl 2-(4-hydroxybenzoyl)hydrazinecarboxylate;
tert-Butyl 2-{4-[(1S)-1-benzyl-2-(benzyloxy)-2-oxoethoxy]benzoyl}hydrazinecarboxylate;
Methyl-4-(5-iodo-2,3-dioxo-2,3-dihydro-1H-indol-1-yl)butanoate; and
tert-Butyl 2-[4-({[4-(3-methoxy-3-oxopropyl)phenyl]sulfonyl}amino)benzoyl]hydrazine-carboxylate.

### Claim 26

A method for modulating the activity of a protein tyrosine phosphatase (PTP), which comprises:
contacting at least one PTP with an oxindole hydrazide derivative according to formula (I)
as well as its tautomers, geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein
R1 is halogen or —(C═O)N—(C6-C18)-alkyl, d is 1 to 4;
R2 is H, —CO—NH—R or —(CH2)u—CO—OR, wherein u is an integer from 1 to 7 and R is H or (C1-C6)-alkyl;
R3 is H or C1-C6-alkyl;
R4, R5, R6 and R7 are each independently from each other selected from the group consisting of H, halogen, —NO2, —OH, (C1-C6)-alkyl, 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl which may contain 1-2 further heteroatoms selected from O, N or S, (C1-C6)-alkyl-heterocycloalkyl wherein said heterocyclolalkyl may contain 1-2 further heteroatoms selected from O, N or S, aryl, (C1-C6)-alkyl-aryl, heteroaryl, (C1-C6)-alkyl-heteroaryl;
R8 is selected from the group comprising or consisting of H, halogen, hydroxy, acyl, amino, carboxy, cyano, nitro, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkyl carboxy, C1-C6-alkyl acyl, C1-C6-alkyl alkoxycarbonyl, carbonylamino, hydrazinocarbonyl, aminocarbonyl, C1-C6-alkyl aminocarbonyl, C1-C6-alkyl acyloxy, acylamino, C1-C6-alkyl acylamino, ureido, C1-C6-alkyl ureido, C1-C6-alkyl carbamate, C1-C6-alkyl amino, C1-C6 alkoxy, C1-C6-alkyl alkoxy, sulfanyl, C1-C6-alkyl sulfanyl, sulfinyl, C1-C6-alkyl sulfinyl, sulfonyl, sulfonylamino, C1-C6-alkyl sulfonyl, C1-C6-alkyl sulfonylaminoaryl, aryl, heteroaryl, C3-C8-cycloalkyl or heterocycloalkyl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl, C2-C6-alkenyl-aryl or -heteroaryl, C2-C6-alkynyl aryl or -heteroaryl
A is selected from the group consisting of a bond, —O—, —S—, —SO—, —SO2—, amino, urea, sulfonylamino or acylamino;
B is arylene, heteroarylene, heterocycloalkylene or cycloalkylene;
X is C, S or SO;
m, n and p are each independently from each other an integer from 0 to 6; m is also 0, 1 or 2, while n is 0 or 1, and p is 1 or 2.

### Claim 27 (depends on 26)

A method according to claim 26, wherein at least one PTP is selected from the group consisting of PTP1B, TC-PTP, SHP, and GLEPP-1.

### Claim 28 (depends on 26)

A method according to claim 26, wherein at least one PTP is PTP1B.

### Claim 29 (depends on 27)

A method according to claim 27, wherein said modulating occurs by reducing the activity of PTP1B.

### Claim 30 (depends on 26)

A method according to claim 26, wherein said contacting occurs in a patient in need of treating or preventing a disorder mediated by PTP1B.
